ADIL Share Price | Adial Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: How big is Adial Pharmaceuticals, Inc.?

Market Cap: As of Jun 18, Adial Pharmaceuticals, Inc. has a market capitalization of 2.51 million, classifying it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Adial Pharmaceuticals, Inc. reported net sales of 0.00 million and a net profit of -8.95 million.Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 4.07 million, while total assets were reported at 5.08 million.

Q: What does Adial Pharmaceuticals, Inc. do?

Overview:Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of medications for the treatment of addictions and related disorders, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025)Market cap: USD 2.51 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -1.11Return on Equity: -420.83%Price to Book: 1.18Contact Details:Address: 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA: 22901Tel: ['1 434 4229800', '1 212 6711021']Fax: 1 302 6555049Website: https://www.adialpharma.com/

Q: Is Adial Pharmaceuticals, Inc. technically bullish or bearish?

As of 1 July 2025, the technical trend for Adial Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, with key indicators showing mixed signals. The MACD is mildly bullish on both weekly and monthly time frames, while the Bollinger Bands indicate a mildly bearish trend weekly and bearish monthly. Moving averages are bearish on a daily basis. The KST and OBV are mildly bullish and bullish respectively on the monthly time frame, but the RSI shows no signal. In terms of performance, the stock has significantly underperformed compared to the S&P 500 across all multi-period returns, with a year-to-date decline of 65.20% versus the S&P 500's gain of 12.22%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

134.31 k

Shareholding (Sep 2025)

FII

0.08%

Held by 3 FIIs

DII

99.12%

Held by 1 DIIs

Promoter

0.00%

How big is Adial Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Adial Pharmaceuticals, Inc. has a market capitalization of 2.51 million, with net sales of 0.00 million and a net profit of -8.95 million over the last four quarters. The company's shareholder's funds are 4.07 million, and total assets are 5.08 million.

View full answer

What does Adial Pharmaceuticals, Inc. do?

22-Jun-2025

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for addictions and related disorders, with a market cap of $2.51 million and a recent net profit of -$2 million. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap entity.

View full answer

Who are in the management team of Adial Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Adial Pharmaceuticals, Inc. includes President and CEO William Stilley, Vice Chairman Kevin Schuyler, and Independent Directors J. Kermit Anderson, Robertson Gilliland, Tony Goodman, and James Newman. They are responsible for the company's strategic direction and operations.

View full answer

Is Adial Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of July 1, 2025, Adial Pharmaceuticals, Inc. is in a mildly bearish trend with mixed technical indicators, significantly underperforming the S&P 500 with a year-to-date decline of 65.20%.

View full answer

Compare Adial Pharmaceuticals, Inc. with Similar Stocks

Dermata Therapeutics, Inc.180 Life Sciences Corp.Plus Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 5 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.02

Return on Equity

-178.73%

Price to Book

1.05

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-57.89%

6 Months

-67.02%

1 Year

-82.43%

2 Years

-87.77%

3 Years

-67.4%

4 Years

-99.77%

5 Years

-94.17%

Adial Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-0.87%

EBIT to Interest (avg)

-11.67

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.11

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

3.92%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.12

EV to EBIT

-0.25

EV to EBITDA

-0.25

EV to Capital Employed

-2.15

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-420.83%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Sideways

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 2 Schemes (0.8%)

Foreign Institutions

Held by 3 Foreign Institutions (0.08%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 20.00% vs -66.67% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.90",
          "val2": "-2.30",
          "chgp": "17.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.00",
          "val2": "-2.50",
          "chgp": "20.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -88.57% vs 35.19% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.30",
          "val2": "-6.90",
          "chgp": "-20.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.20",
          "val2": "-7.00",
          "chgp": "-88.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-1.90

-2.30

17.39%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-2.00

-2.50

20.00%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 20.00% vs -66.67% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-8.30

-6.90

-20.29%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-13.20

-7.00

-88.57%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -88.57% vs 35.19% in Dec 2023

All Annual Results

Company CV

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of medications for the treatment of addictions and related disorders. Its lead investigational drug product is AD04. AD04 is being developed for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist. AD04 is being designed to be used for the treatment of other addictive disorders, such as opioid use disorder, obesity, smoking, and other drug addictions.

Company Coordinates

Company Details

1180 SEMINOLE TRAIL, SUITE 495 , CHARLOTTESVILLE VA : 22901

Tel: 1 434 42298001 212 6711021

https://www.adialpharma.com/

Registrar Details

Adial Pharmaceuticals, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Adial Pharmaceuticals, Inc.?

Watch in Real-Time

What does Adial Pharmaceuticals, Inc. do?

Who are in the management team of Adial Pharmaceuticals, Inc.?

Is Adial Pharmaceuticals, Inc. technically bullish or bearish?

Compare Adial Pharmaceuticals, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Adial Pharmaceuticals, Inc.

Company Coordinates